This guide offers a strategic consultation framework for successful pharmaceutical market entry in GCC, covering regulatory compliance, SFDA/MoHAP registration, pharmacovigilance, pricing, tender readiness, and post-marketing surveillance.
A Proven GCC Launch Playbook: Strategic Consultation for Pharmaceutical Market Entry Read More »
In 2026, GCC biotech regulations evolve with Saudi SFDA’s detailed clinical data and local manufacturing focus, UAE’s streamlined eCTD submissions, Oman’s GCC-aligned standards, and stricter biologics and ATMP rules across Qatar, Kuwait, and others, emphasizing GMP/GxP compliance, real-world evidence, decentralized trials, and strategic use of Egypt and Saudi regulatory hubs.
GCC Regulatory Trends Biotech Must Watch in 2026 Read More »
PharmaOasis guides pharmaceutical firms through complex Middle East and GCC regulatory affairs, offering tailored strategies, dossier management, and compliance expertise for seamless market entry and ongoing safety.
Your Gateway to Middle East and GCC Regulatory Affairs: A Comprehensive Guide Read More »
GCC pharmaceutical regulations are evolving with centralized registration, stricter Saudi SFDA/UAE MoHAP policies, enhanced pharmacovigilance, digital submissions, and growing use of real-world evidence.
Emerging Trends Shaping Pharmaceutical Regulations in the GCC and Middle East Read More »
